

Press release
Lund 04 MAR 2020

Scandinavian ChemoTech continues its launch in Africa by receiving a new agreement and orders

ChemoTech is expanding in Africa by signing a collaboration agreement for clinical validation and distribution with Femaug Logistics and Services Ltd (FLS) in Nigeria. In conjunction with this agreement, ChemoTech will receive two orders for a total value of EUR 50,000.

The agreement is intended to initially secure a collaboration where leading doctors and decision-makers in Nigeria receive education and the opportunity to gather important clinical data for continued launch in the country and in the economic West African property, EKOWAS, a region with nearly 400 million inhabitants.

“It’s extremely exciting that we can now begin a long-term endeavour in West Africa with the aim of creating important clinical evidence and relationships with leading oncologists. We start our establishment process in Nigeria and ECOWAS with two orders, however, it is only after the clinical evidence from studies or clinical evaluation that D-EECT will be able to be launched on a larger scale within Nigeria's public healthcare system”- Mohan Frick, CEO

ChemoTech's co-founder Dr. Göran Hellers, who has long experience of establishing medical technology in oncology in ECOWAS, will together with FLS be responsible for ChemoTech's establishment work in the region.

Femaug Logistics and Services Ltd is a Nigerian based marketing and distribution company that specialises in the marketing and distribution of medical devices and services. The CEO and Co-Founder Temitope Akintaju and his partner Femi Israel has extensive experiences in medical technology and in Nigerian and Swedish business relations.

For more information, please contact:
Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00
info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250,
E-mail: ca@vhcorp.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by

the agency of above stated contact person, to be made public on Wednesday 04th of March 2020 at 11.30 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.